On Jul. 1, 2020, Intravacc announced the signing of a strategic partnership agreement with Dutch based CimCure, focusing on cancer immunotherapies for solid tumors, for in- licensing CimCure’s iBoost technology.

This agreement offered Intravacc access to this technology in developing new vaccines and for providing services involving the in-licensed technique in mutually agreed countries. This technology also enabled Intravacc to expand its translational expertise towards the development of cancer vaccines.